Barbara Breznik

TL;DR: Focusing on one stromal component in the glioblastoma niches, the mesenchymal stem cells (MSCs), the major hindrance to metastatic progression of mCSCs seem to be crossing the blood-brain-barrier in brain metastases.

TL;DR: It is demonstrated that MSC/glioblastomas cross-talk is different in the two glioblastoma cell phenotypes, which contributes to tumor heterogeneity.

TL;DR: Mechanistic studies of cystatin function revealed that they affect all stages of cancer progression including tumor growth, apoptosis, invasion, metastasis and angiogenesis, and involvement in anti-tumor immune response and signaling cascades leading to cancer progression designates cystatins as possible targets for development of new anti-Tumor drugs.

TL;DR: In this paper, the authors summarize the glioblastoma characteristics that drive tolerance to immunotherapy, the currently used immunotherapeutic approaches, and the most suitable tumor models to mimic conditions in brain malignant tumor patients.

TL;DR: Autocrine and paracrine cross-talk in glioblastoma and, in particular, gli oblastoma stem cells with its stromal microenvironment, involves CCR5 and CCL5, contributing to gliOBlastoma invasion, suggesting the CCL 5/CCR5 axis as a potential therapeutic target that can be targeted with repositioned drug maraviroc.